Cormorant Asset Management, LP 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Cormorant Asset Management, LP disclosed 45 US equity positions worth $1.9bn in its Q3 2024 13F filing. The largest position was MLTX at 22.7% of the reported book, followed by PCVX and ACLXGBX.
What did Cormorant Asset Management, LP own in Q3 2024? Top 45 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 22.7% | $428.3m | 8,494,151 | – | |
| 2 | PCVX VAXCYTE INC | Healthcare | 6.1% | $114.3m | 1,000,000 | – | |
| 3 | ACLXGBX ARCELLX INC | 5.5% | $104.4m | 1,250,000 | – | ||
| 4 | LONGBOARD PHARMACEUTICALS IN | 4.9% | $93.0m | 2,790,462 | – | ||
| 5 | EWTX EDGEWISE THERAPEUTICS INC | 4.8% | $90.9m | 3,406,534 | – | ||
| 6 | EYPT EYEPOINT PHARMACEUTICALS INC | Healthcare | 3.5% | $66.5m | 8,325,000 | – | |
| 7 | RAPP RAPPORT THERAPEUTICS INC | 3.2% | $60.2m | 2,940,921 | – | ||
| 8 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 3.0% | $56.2m | 1,100,000 | – | ||
| 9 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 2.7% | $50.1m | 870,000 | – | |
| 10 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 2.6% | $49.0m | 2,375,000 | – | |
| 11 | RNAGBP AVIDITY BIOSCIENCES INC | 2.6% | $48.2m | 1,050,000 | – | ||
| 12 | JANX JANUX THERAPEUTICS INC | Healthcare | 2.5% | $47.7m | 1,050,000 | – | |
| 13 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 2.5% | $47.3m | 1,858,351 | – | |
| 14 | NEWAMSTERDAM PHARMA COMPANY | 2.2% | $41.0m | 2,470,000 | – | ||
| 15 | CNTA CENTESSA PHARMACEUTICALS PLC | 2.2% | $41.0m | 2,561,600 | – | ||
| 16 | MERUS N V | 2.0% | $37.0m | 740,000 | – | ||
| 17 | CGON CG ONCOLOGY INC | Healthcare | 2.0% | $36.8m | 975,000 | – | |
| 18 | INSM INSMED INC | Healthcare | 1.9% | $36.5m | 500,000 | – | |
| 19 | BMEA BIOMEA FUSION INC | 1.9% | $36.1m | 3,570,872 | – | ||
| 20 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.9% | $35.9m | 400,000 | – | |
| 21 | BIOA BIOAGE LABS INC | 1.8% | $33.9m | 1,629,529 | – | ||
| 22 | HELIX ACQUISITION CORP II | 1.6% | $30.4m | 2,909,000 | – | ||
| 23 | PHVS PHARVARIS N V | 1.4% | $27.2m | 1,466,460 | – | ||
| 24 | ABVX ABIVAX SA | 1.3% | $24.5m | 2,130,000 | – | ||
| 25 | ALMS ALUMIS INC | 1.2% | $22.9m | 2,147,396 | – | ||
| 26 | CRGX CARGO THERAPEUTICS INC | 1.2% | $21.8m | 1,182,563 | – | ||
| 27 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 1.1% | $21.6m | 2,325,000 | – | |
| 28 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 1.1% | $21.0m | 400,000 | – | |
| 29 | BHVN BIOHAVEN LTD | Healthcare | 1.1% | $20.1m | 401,963 | – | |
| 30 | URGN UROGEN PHARMA LTD | Healthcare | 1.0% | $19.7m | 1,550,000 | – | |
| 31 | YMABUSD Y-MABS THERAPEUTICS INC | 1.0% | $19.1m | 1,450,000 | – | ||
| 32 | MBX MBX BIOSCIENCES INC | Healthcare | 1.0% | $18.2m | 700,000 | – | |
| 33 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 0.9% | $16.4m | 500,000 | – | |
| 34 | AVBP ARRIVENT BIOPHARMA INC | 0.7% | $13.8m | 585,462 | – | ||
| 35 | ANAB ANAPTYSBIO INC | Healthcare | 0.6% | $11.5m | 342,465 | – | |
| 36 | KRRO KORRO BIO INC | Healthcare | 0.5% | $8.9m | 265,826 | – | |
| 37 | SLN SILENCE THERAPEUTICS PLC | 0.4% | $7.3m | 400,000 | – | ||
| 38 | ENGENE HOLDINGS INC | 0.3% | $6.6m | 1,000,000 | – | ||
| 39 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.3% | $5.2m | 427,163 | – | |
| 40 | NGNE NEUROGENE INC | 0.2% | $4.5m | 107,344 | – | ||
| 41 | GHRS GH RESEARCH PLC | 0.2% | $4.0m | 593,043 | – | ||
| 42 | MNLOUSD VYNE THERAPEUTICS INC | 0.1% | $2.6m | 1,394,336 | – | ||
| 43 | VERVE THERAPEUTICS INC | 0.1% | $1.7m | 350,000 | – | ||
| 44 | ARTV ARTIVA BIOTHERAPEUTICS INC | 0.1% | $1.6m | 103,633 | – | ||
| 45 | RAPT THERAPEUTICS INC | 0.1% | $998.5k | 496,750 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.